dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Felip Font, Enriqueta |
dc.contributor.author | Morgensztern, Daniel |
dc.contributor.author | Trigo, José Manuel |
dc.contributor.author | Moreno, Victor |
dc.contributor.author | Curigliano, Giuseppe |
dc.contributor.author | Rutkowski, Piotr |
dc.date.accessioned | 2022-08-10T06:25:51Z |
dc.date.available | 2022-08-10T06:25:51Z |
dc.date.issued | 2022-04 |
dc.identifier.citation | Felip E, Moreno V, Morgensztern D, Curigliano G, Rutkowski P, Trigo JM, et al. First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. Cancer Chemother Pharmacol. 2022 Apr;89:499–514. |
dc.identifier.issn | 1432-0843 |
dc.identifier.uri | https://hdl.handle.net/11351/7973 |
dc.description | Melanoma; Monoclonal antibody PD-1 inhibitor efficacy; Pharmacokinetics/pharmacodynamics |
dc.description.abstract | Purpose
To assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of cetrelimab (JNJ-63723283), a monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor, in patients with advanced/refractory solid tumors in the phase 1/2 LUC1001 study.
Methods
In phase 1, patients with advanced solid tumors received intravenous cetrelimab 80, 240, 460, or 800 mg every 2 weeks (Q2W) or 480 mg Q4W. In phase 2, patients with melanoma, non-small-cell lung cancer (NSCLC), and microsatellite instability–high (MSI-H)/DNA mismatch repair-deficient colorectal cancer (CRC) received cetrelimab 240 mg Q2W. Response was assessed Q8W until Week 24 and Q12W thereafter.
Results
In phase 1, 58 patients received cetrelimab. Two dose-limiting toxicities were reported and two recommended phase 2 doses (RP2D) were defined (240 mg Q2W or 480 mg Q4W). After a first dose, mean maximum serum concentrations (Cmax) ranged from 24.7 to 227.0 µg/mL; median time to Cmax ranged from 2.0 to 3.2 h. Pharmacodynamic effect was maintained throughout the dosing period across doses. In phase 2, 146 patients received cetrelimab 240 mg Q2W. Grade ≥ 3 adverse events (AEs) occurred in 53.9% of patients. Immune-related AEs (any grade) occurred in 35.3% of patients (grade ≥ 3 in 6.9%). Overall response rate was 18.6% across tumor types, 34.3% in NSCLC, 52.6% in programmed death ligand 1–high (≥ 50% by immunohistochemistry) NSCLC, 28.0% in melanoma, and 23.8% in centrally confirmed MSI-H CRC.
Conclusions
The RP2D for cetrelimab was established. Pharmacokinetic/pharmacodynamic characteristics, safety profile, and clinical activity of cetrelimab in immune-sensitive advanced cancers were consistent with known PD-1 inhibitors. |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Cancer Chemotherapy and Pharmacology;89 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Càncer - Tractament |
dc.subject | Anticossos monoclonals - Ús terapèutic - Eficàcia |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | /drug therapy |
dc.title | First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s00280-022-04414-6 |
dc.subject.decs | neoplasias |
dc.subject.decs | /farmacoterapia |
dc.relation.publishversion | https://doi.org/10.1007/s00280-022-04414-6 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Felip E] Unitat de Càncer Toràcic, Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Moreno V] Phase 1 Trials Unit, START MADRID-FJD, Hospital Fundación Jiménez Díaz Medical Oncology Division, Madrid, Spain. [Morgensztern D] Division of Oncology, Section of Medical Oncology, Washington University School of Medicine, St. Louis, MO, USA. [Curigliano G] Division of Early Drug Development, European Institute of Oncology, IRCCS and University of Milano, Milan, Italy. [Rutkowski P] Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland. [Trigo JM] Department of Medical Oncology, Hospital Universitario Virgen de La Victoria y Regional, Málaga, Spain |
dc.identifier.pmid | 35298698 |
dc.identifier.wos | 000770203700002 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |